Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

A series of novel tricyclic quinoxaline derivatives was prepared and examined on SRPK-1 kinase assay and on a selectivity panel of 19 kinase assays.Figure optionsDownload as PowerPoint slide